PubMed · 1996 · 51 citations · 19 references
Life SciencesImmunologyOncologyCancer ImmunologyImmunotherapyTumor ImmunologyAntitumor T Cell ResponsesCancer ImmunotherapyImmunotherapy For Breast CancerT Cell Responses To TumorsTumor AntigensTumor-infiltrating LymphocytesAntigen Recognition By Cytotoxic T LymphocytesCd8+ Tumor-infiltrating LymphocytesTumor ImmunogenicityTumor-associated Antigen RecognitionTumor-associated Antigen TargetingTumor-associated Antigen VaccinesVaccinia Virus VectorsViral Vector Cancer Vaccines
A potential target for development of tumor-specific immunotherapeutic strategies is the MAGE-1 gene. We have utilized a recently developed recombinant canarypox (ALVAC) virus vector containing the MAGE-1 gene (vCP235) to activate CTLs from a breast cancer patient bearing a MAGE-1+ tumor. Tumor-infiltrating lymphocytes (TILs) obtained from the tumor of a patient were stimulated in vitro with irradiated autologous peripheral blood mononuclear cells acutely infected with the vCP235 construct. These TILs preferentially expanded approximately 6-fold over a 16-day culture period and specifically recognized an allogeneic transformed B-cell line acutely infected with a vaccinia-MAGE-1 recombinant targeting vector (vP1188) in the context of HLA-A2 and/or B7. TCR V beta analysis of in vitro expanded T cells by a quantitative multiprobe RNase protection assay revealed preferential expansion of TCR V beta 6.3 and V beta 6.4. In addition, homologous T-cell receptor beta CDR3 joining sequences were found in the in vitro stimulated cultures. These results suggest that tumor antigen-specific, MHC-restricted CTLs may be derived from precursor CTLs present in TILs obtained from patients with MAGE-1+ tumors by in vitro stimulation with recombinant avipox MAGE-1 virus-infected autologous cells. Collectively, these findings provide a rationale for tumor-associated antigen-based immunization as a means of activating precursor CTLs residing in patients with tumors expressing defined tumor-associated antigens such as MAGE-1.
19
NYVAC: A highly attenuated strain of vaccinia virus
James Tartaglia, Marion E. Perkus, J TAYLOR et al. · Virology · 1992 · 471 citations
Existent T-cell and antibody immunity to HER-2/neu protein in patients with breast cancer.
Mary L. Disis, Emanuel Calenoff, Graham McLaughlin et al. · PubMed · 1994 · 467 citations
Life Sciences, Immunology, Oncology +17